BioSante Pharmaceuticals, Inc. (BPAX)

[homeslice10]

spunky what do you make of this study, do you think W Wolfman MD is a fraud? Is U of Toronto misguiding the scientific community? Do you think this journal article skipped peer review?:

J Obstet Gynaecol Can. 2012 Sep;34(9):859-65.
The safety of testosterone therapy in women.
Al-Imari L, Wolfman WL.
Source

University of Toronto, Toronto ON.
Abstract

Hypoactive sexual desire disorder (HSDD), a subset of female sexual dysfunction, causes personal distress for surgically and naturally postmenopausal and premenopausal women. HSDD has a multi-factorial etiology, including psychosocial factors such as relationship issues and medical factors such as medications, chronic illnesses, and hormonal effects. Although no androgen therapies for female sexual dysfunction are currently approved for use in Canada, clinical trials support the efficacy and short-term safety of testosterone therapy for HSDD. We review the scientific evidence for the safety of testosterone therapy for HSDD.